NCT05538156

Brief Summary

Despite advances in surgical techniques over the recent decades, proliferative vitreoretinopathy (PVR) remains the main obstacle to successful rhegmatogenous retinal detachment (RRD) repair, accounting for nearly 75% of all primary surgical failures. It is characterized by the growth and contraction of cellular membranes within the vitreous cavity and on both surfaces of the detached retina as well as intraretinal fibrosis. The Retina Society classification, modified in 1991 and currently the most widely used, divided PVR into three grades. Grade A is limited to the presence of vitreous haze and pigment clumps. Grade B includes rolled or irregular edges of tear and/or inner retinal surface wrinkling with possible retinal stiffness and vessel tortuosity. Grade C is defined as the presence of full-thickness fixed retinal folds and is further subdivided based on the number of hours involved and the location. Recently, Foveau et al., in a retrospective comparative case series, have demonstrated that performing internal limiting membrane (ILM) peeling during RRD surgery may increase the anatomical success rate for this indication. The aim of this multi-center, prospective, randomized controlled clinical trial study is to evaluate the effectiveness of ILM peeling on surgical outcomes in patients with primary macula-off RRD complicated by grade B PVR.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
126

participants targeted

Target at P50-P75 for not_applicable

Timeline
19mo left

Started Sep 2022

Longer than P75 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress70%
Sep 2022Dec 2027

Study Start

First participant enrolled

September 1, 2022

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

September 9, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 13, 2022

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2026

Expected
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Last Updated

September 13, 2022

Status Verified

July 1, 2022

Enrollment Period

4 years

First QC Date

September 9, 2022

Last Update Submit

September 9, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Primary anatomical success rate

    Primary retinal reattachment rate

    12 months after surgery

Secondary Outcomes (7)

  • Functional outcomes #1

    12 months after surgery

  • Functional outcomes #2

    12 months after surgery

  • Anatomical outcomes #1

    12 months after surgery

  • Anatomical outcomes #2

    12 months after surgery

  • Anatomical outcomes #3

    12 months after surgery

  • +2 more secondary outcomes

Study Arms (2)

Control group

OTHER

The internal limiting membrane is not removed

Procedure: Control group

Intervention group

OTHER

The internal limiting membrane of the posterior pole is removed

Procedure: Intervention group

Interventions

Control groupPROCEDURE

Vitrectomy and gas tamponade without internal limiting membrane peeling

Control group

Vitrectomy, internal limiting membrane peeling and gas tamponade

Intervention group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients older than 18 years old
  • With macula-off retinal detachment complicated by grade B proliferative vitreoretinopathy

You may not qualify if:

  • Underage patients
  • History of retinal detachment
  • History of intraocular surgery (except for cataract surgery)
  • Traumatic retinal detachment
  • Macular hole-associated retinal detachment
  • Concurrent macular disease (diabetic maculopathy, age-related macular degeneration)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (6)

  • Borowicz D, Nowomiejska K, Nowakowska D, Brzozowska A, Toro MD, Avitabile T, Junemann AG, Rejdak R. Functional and morphological results of treatment of macula-on and macula-off rhegmatogenous retinal detachment with pars plana vitrectomy and sulfur hexafluoride gas tamponade. BMC Ophthalmol. 2019 May 24;19(1):118. doi: 10.1186/s12886-019-1120-3.

  • Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol. 1995 Oct;79(10):953-60. doi: 10.1136/bjo.79.10.953. No abstract available.

  • Eissa MGAM, Abdelhakim MASE, Macky TA, Khafagy MM, Mortada HA. Functional and structural outcomes of ILM peeling in uncomplicated macula-off RRD using microperimetry & en-face OCT. Graefes Arch Clin Exp Ophthalmol. 2018 Feb;256(2):249-257. doi: 10.1007/s00417-017-3875-7. Epub 2018 Jan 3.

  • Fallico M, Russo A, Longo A, Pulvirenti A, Avitabile T, Bonfiglio V, Castellino N, Cennamo G, Reibaldi M. Internal limiting membrane peeling versus no peeling during primary vitrectomy for rhegmatogenous retinal detachment: A systematic review and meta-analysis. PLoS One. 2018 Jul 19;13(7):e0201010. doi: 10.1371/journal.pone.0201010. eCollection 2018.

  • Foveau P, Leroy B, Berrod JP, Conart JB. Internal Limiting Membrane Peeling in Macula-off Retinal Detachment Complicated by Grade B Proliferative Vitreoretinopathy. Am J Ophthalmol. 2018 Jul;191:1-6. doi: 10.1016/j.ajo.2018.03.037. Epub 2018 Apr 3.

  • Steel DH, Joussen AM, Wong D. ILM peeling in rhegmatogenous retinal detachment; does it improve the outcome? Graefes Arch Clin Exp Ophthalmol. 2018 Feb;256(2):247-248. doi: 10.1007/s00417-017-3876-6. Epub 2017 Dec 27. No abstract available.

MeSH Terms

Conditions

Retinal DetachmentVitreoretinopathy, Proliferative

Interventions

Control Groups

Condition Hierarchy (Ancestors)

Retinal DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Study Officials

  • Jean-Baptiste CONART, Prof

    Brabois Hospital, Nancy, France

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jean-Baptiste CONART, Prof

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 9, 2022

First Posted

September 13, 2022

Study Start

September 1, 2022

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

December 1, 2027

Last Updated

September 13, 2022

Record last verified: 2022-07

Data Sharing

IPD Sharing
Will not share